Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

Dosing initiated in combination Phase I study of palifosfamide with etoposide and cisplatin/carboplatin in SCLC

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Xeloda may reduce recurrence of faster growing breast cancers: Study

Xeloda may reduce recurrence of faster growing breast cancers: Study

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Preclinical data of ZIO-101 in various lymphoma models presented at ASH 2010

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Research reveals new standard treatment options for various forms of lymphoma

Research reveals new standard treatment options for various forms of lymphoma

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

New standard treatment for early stage breast cancer

New standard treatment for early stage breast cancer

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Accentia and Biovest exit Chapter 11 as fully restructured organizations

Accentia and Biovest exit Chapter 11 as fully restructured organizations

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer